The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues
BackgroundNeuroendocrine prostate cancer (NEPCa) is the most aggressive type of prostate cancer (PCa). However, energy metabolism, one of the hallmarks of cancer, in NEPCa has not been well studied. Pyruvate kinase M (PKM), which catalyzes the final step of glycolysis, has two main splicing isoforms...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1392085/full |
| _version_ | 1797213475304374272 |
|---|---|
| author | Lin Li Lin Li Siyuan Cheng Siyuan Cheng Yunshin Yeh Yingli Shi Yingli Shi Nikayla Henderson David Price Xin Gu Xiuping Yu Xiuping Yu Xiuping Yu |
| author_facet | Lin Li Lin Li Siyuan Cheng Siyuan Cheng Yunshin Yeh Yingli Shi Yingli Shi Nikayla Henderson David Price Xin Gu Xiuping Yu Xiuping Yu Xiuping Yu |
| author_sort | Lin Li |
| collection | DOAJ |
| description | BackgroundNeuroendocrine prostate cancer (NEPCa) is the most aggressive type of prostate cancer (PCa). However, energy metabolism, one of the hallmarks of cancer, in NEPCa has not been well studied. Pyruvate kinase M (PKM), which catalyzes the final step of glycolysis, has two main splicing isoforms, PKM1 and PKM2. The expression pattern of PKM1 and PKM2 in NEPCa remains unknown.MethodsIn this study, we used immunohistochemistry, immunofluorescence staining, and bioinformatics analysis to examine the expression of PKM1 and PKM2 in mouse and human prostatic tissues.ResultsWe found that PKM2 was the predominant isoform expressed throughout prostate development and PCa progression, with slightly reduced expression in murine NEPCa. PKM1 was mostly expressed in stromal cells but low-level PKM1 was also detected in prostate basal epithelial cells. Its expression was absent in the majority of prostate adenocarcinoma (AdPCa) specimens but present in a subset of NEPCa. Additionally, we evaluated the mRNA levels of ten PKM isoforms that express exon 9 (PKM1-like) or exon 10 (PKM2-like). Some of these isoforms showed notable expression levels in PCa cell lines and human PCa specimens.DiscussionOur study characterized the expression pattern of PKM1 and PKM2 in prostatic tissues including developing, benign, and cancerous prostate. These findings lay the groundwork for understanding the metabolic changes in different PCa subtypes. |
| first_indexed | 2024-04-24T10:58:52Z |
| format | Article |
| id | doaj.art-ba1a2f366d1546e3919fc2496c548a8c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T10:58:52Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ba1a2f366d1546e3919fc2496c548a8c2024-04-12T04:27:00ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13920851392085The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissuesLin Li0Lin Li1Siyuan Cheng2Siyuan Cheng3Yunshin Yeh4Yingli Shi5Yingli Shi6Nikayla Henderson7David Price8Xin Gu9Xiuping Yu10Xiuping Yu11Xiuping Yu12Department of Biochemistry and Molecular Biology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesFeist-Weiller Cancer Center, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Biochemistry and Molecular Biology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesFeist-Weiller Cancer Center, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesPathology & Laboratory Medicine Service, Overton Brooks VA Medical Center, Shreveport, LA, United StatesDepartment of Biochemistry and Molecular Biology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesFeist-Weiller Cancer Center, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Biochemistry and Molecular Biology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Urology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Pathology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Biochemistry and Molecular Biology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesFeist-Weiller Cancer Center, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesDepartment of Urology, LSU Health Sciences Center at Shreveport, Shreveport, LA, United StatesBackgroundNeuroendocrine prostate cancer (NEPCa) is the most aggressive type of prostate cancer (PCa). However, energy metabolism, one of the hallmarks of cancer, in NEPCa has not been well studied. Pyruvate kinase M (PKM), which catalyzes the final step of glycolysis, has two main splicing isoforms, PKM1 and PKM2. The expression pattern of PKM1 and PKM2 in NEPCa remains unknown.MethodsIn this study, we used immunohistochemistry, immunofluorescence staining, and bioinformatics analysis to examine the expression of PKM1 and PKM2 in mouse and human prostatic tissues.ResultsWe found that PKM2 was the predominant isoform expressed throughout prostate development and PCa progression, with slightly reduced expression in murine NEPCa. PKM1 was mostly expressed in stromal cells but low-level PKM1 was also detected in prostate basal epithelial cells. Its expression was absent in the majority of prostate adenocarcinoma (AdPCa) specimens but present in a subset of NEPCa. Additionally, we evaluated the mRNA levels of ten PKM isoforms that express exon 9 (PKM1-like) or exon 10 (PKM2-like). Some of these isoforms showed notable expression levels in PCa cell lines and human PCa specimens.DiscussionOur study characterized the expression pattern of PKM1 and PKM2 in prostatic tissues including developing, benign, and cancerous prostate. These findings lay the groundwork for understanding the metabolic changes in different PCa subtypes.https://www.frontiersin.org/articles/10.3389/fonc.2024.1392085/fullPKM1PKM2neuroendocrineprostate cancermetabolism |
| spellingShingle | Lin Li Lin Li Siyuan Cheng Siyuan Cheng Yunshin Yeh Yingli Shi Yingli Shi Nikayla Henderson David Price Xin Gu Xiuping Yu Xiuping Yu Xiuping Yu The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues Frontiers in Oncology PKM1 PKM2 neuroendocrine prostate cancer metabolism |
| title | The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues |
| title_full | The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues |
| title_fullStr | The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues |
| title_full_unstemmed | The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues |
| title_short | The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues |
| title_sort | expression of pkm1 and pkm2 in developing benign and cancerous prostatic tissues |
| topic | PKM1 PKM2 neuroendocrine prostate cancer metabolism |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1392085/full |
| work_keys_str_mv | AT linli theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT linli theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT siyuancheng theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT siyuancheng theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yunshinyeh theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yinglishi theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yinglishi theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT nikaylahenderson theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT davidprice theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xingu theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu theexpressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT linli expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT linli expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT siyuancheng expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT siyuancheng expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yunshinyeh expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yinglishi expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT yinglishi expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT nikaylahenderson expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT davidprice expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xingu expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues AT xiupingyu expressionofpkm1andpkm2indevelopingbenignandcancerousprostatictissues |